HDAC2 and breast cancer: However, in BC, after MPA treatment, TRPS1 was identified as a transcription coactivator, PR recruited TRPS1 but did not interact with HDAC2 in the specific breast cell context, thus accelerating the acetylation of RANKL and enhancing the cancer-promoting effect of MPA (Fig. 8).